CU-Boulder’s AVR-Chip can find mutations related to resistance and BChip can pick out influenza B virus strains.

Quidel gained exclusive, worldwide rights to the antiviral resistance microarray-based influenza detection technology (AVR-Chip) and the microarray-based influenza B detection technology (BChip) from the University of Colorado at Boulder (CU-Boulder).

“Exclusive access to molecular-based technologies for influenza B diagnostics and for detection of antiviral resistance, greatly complements our ongoing progress with our MChip technology for influenza A, which was licensed in December 2006 from CU-Boulder, ” states Caren Mason, president and CEO.

The AVR-Chip can identify mutations that may confer resistance to antiviral reagents and may then facilitate proper influenza treatment decisions. The BChip can detect influenza B virus strains. In a study of 62 influenza B virus samples from 19 countries, dating from 1945 to 2005, as well as five negative control samples, the BChip exhibited 97% sensitivity and 100% specificity with no false positives, according to Quidel.

Previous articlePharmacopeia Earns Milestone Payment in GSK Partnership
Next articleScientists Discover Mechanism of Side Effects for HIV Drugs